'Cancer will be history in 10 years': Anthropic CEO's big AI-powered promise
Anthropic is collaborating with various biotechnology firms to utilize AI for accelerating drug discovery and medical research. The company claims these AI-driven efforts could significantly reduce the time and cost required to develop treatments for cancer and other diseases.
Why it matters
This represents a major shift in pharmaceutical R&D, where generative AI is being applied to solve complex biological problems and speed up life-saving medical breakthroughs.
Anthropic is stepping up its efforts to use artificial intelligence (AI) to accelerate drug discovery, working with biotechnology companies to develop potential treatments for cancer, food allergies and rare diseases.The company behind AI chatbot Claude said it has partnered with six organisations, including Bristol Myers Squibb, Generate Biomedicines and BigHat Biosciences, to explore how AI can speed up different stages of developing new medicines.The announcement comes amid growing interest in the use of AI to identify potential drugs, design molecules and reduce the time and cost involved in medical research.AI helps develop potential cancer treatmentsOne of the projects involves Generate Biomedicines, which is working to adapt CAR T-cell therapy, traditionally used against blood cancers, to treat solid tumours.Using Claude Code, six scientists from Generate proposed a redesigned version of a section of the therapy's genetic instructions.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in